IOBT
IO Biotech, Inc.
Price Chart
No historical data available
Latest Quote
$0.05
+0.00 (+0.00%)
Current Price
| Previous Close | $0.05 |
| Open | $0.03 |
| Day High | $0.06 |
| Day Low | $0.03 |
| Volume | 469,191,612 |
Stock Information
| Shares Outstanding | 71.95M |
| Total Debt | $18.12M |
| Cash Equivalents | $30.66M |
| Net Income | $-88.35M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.45M |
| EPS (TTM) | $-0.23 |
| Exchange | NMS |
Recent Price History
No history data available. Data will be fetched automatically.
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFÃ1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark. On March 31, 2026, IO Biotech, Inc., along with its affiliate, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
đ° Latest News
Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing
Zacks âĸ 2026-02-13T14:55:02Z
Piper downgrades IO Biotech amid strategic alternatives evaluation
TipRanks âĸ 2026-01-27T13:00:20Z
BC-Most Active Stocks
Associated Press Finance âĸ 2026-01-22T15:30:18ZModerna cancer vaccine holds up; IO Biotech considers a sale
BioPharma Dive âĸ 2026-01-21T10:38:00Z
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why
Zacks âĸ 2025-11-19T17:00:03Z
FDA officialâs comments spark Aurinia sell-off; Halozyme buys a biotech
BioPharma Dive âĸ 2025-10-01T10:00:00Z
IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says
MT Newswires âĸ 2025-09-30T15:06:38ZIO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2025-09-03T16:00:02Z
H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14
Insider Monkey âĸ 2025-08-26T12:39:52Z
IO Biotech to pursue cancer vaccine approval despite Phase III miss
Clinical Trials Arena âĸ 2025-08-11T17:23:43Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $95,177,000 | $91,443,000 | $71,424,000 | $41,234,000 |
| Other Income Expense | $-3,589,000 | $331,000 | $130,000 | $-26,216,000 |
| Net Non Operating Interest Income Expense | $4,718,000 | $5,881,000 | $1,109,000 | $-361,000 |
| Operating Expense | $95,177,000 | $91,443,000 | $71,424,000 | $41,234,000 |
| General And Administrative Expense | $23,693,000 | $23,614,000 | $24,438,000 | $11,082,000 |
| Interest Expense | - | $0 | $302,000 | $361,000 |
| Interest Expense Non Operating | - | $0 | $302,000 | $361,000 |
| Other Non Operating Income Expenses | - | - | - | $-26,535,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-95,491,000 | $-86,083,000 | $-71,458,000 | $-67,879,000 |
| Net Interest Income | $4,718,000 | $5,881,000 | $1,109,000 | $-361,000 |
| Interest Income | $4,718,000 | $5,881,000 | $1,411,000 | $0 |
| Normalized Income | $-92,691,580 | $-86,341,180 | $-71,585,660 | $-68,127,820 |
| Net Income From Continuing And Discontinued Operation | $-95,491,000 | $-86,083,000 | $-71,458,000 | $-67,879,000 |
| Total Operating Income As Reported | $-95,177,000 | $-91,443,000 | $-71,424,000 | $-41,234,000 |
| Net Income Common Stockholders | $-95,491,000 | $-86,083,000 | $-71,458,000 | $-74,987,000 |
| Net Income | $-95,491,000 | $-86,083,000 | $-71,458,000 | $-67,879,000 |
| Net Income Including Noncontrolling Interests | $-95,491,000 | $-86,083,000 | $-71,458,000 | $-67,879,000 |
| Net Income Continuous Operations | $-95,491,000 | $-86,083,000 | $-71,458,000 | $-67,879,000 |
| Pretax Income | $-94,048,000 | $-85,231,000 | $-70,185,000 | $-67,811,000 |
| Interest Income Non Operating | $4,718,000 | $5,881,000 | $1,411,000 | $0 |
| Operating Income | $-95,177,000 | $-91,443,000 | $-71,424,000 | $-41,234,000 |
| Per Share | ||||
| Diluted EPS | $-1.45 | $-1.98 | $-2.48 | $-17.30 |
| Basic EPS | $-1.45 | $-1.98 | $-2.48 | $-17.30 |
| Other | ||||
| Tax Effect Of Unusual Items | $-789,580 | $72,820 | $2,340 | $70,180 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-90,739,000 | $-91,018,000 | $-69,473,000 | $-67,767,000 |
| Total Unusual Items | $-3,589,000 | $331,000 | $130,000 | $319,000 |
| Total Unusual Items Excluding Goodwill | $-3,589,000 | $331,000 | $130,000 | $319,000 |
| Reconciled Depreciation | $849,000 | $756,000 | $540,000 | $2,000 |
| EBITDA (Bullshit earnings) | $-94,328,000 | $-90,687,000 | $-69,343,000 | $-67,448,000 |
| EBIT | $-95,177,000 | $-91,443,000 | $-69,883,000 | $-67,450,000 |
| Diluted Average Shares | $65,880,914 | $43,539,976 | $28,815,267 | $4,335,629 |
| Basic Average Shares | $65,880,914 | $43,539,976 | $28,815,267 | $4,335,629 |
| Diluted NI Availto Com Stockholders | $-95,491,000 | $-86,083,000 | $-71,458,000 | $-74,987,000 |
| Tax Provision | $1,443,000 | $852,000 | $1,273,000 | $68,000 |
| Gain On Sale Of Security | $-3,589,000 | $331,000 | $130,000 | $319,000 |
| Research And Development | $71,484,000 | $67,829,000 | $46,986,000 | $30,152,000 |
| Selling General And Administration | $23,693,000 | $23,614,000 | $24,438,000 | $11,082,000 |
| Other Gand A | $12,326,000 | $13,320,000 | $17,178,000 | $8,126,000 |
| Salaries And Wages | $11,367,000 | $10,294,000 | $7,260,000 | $2,956,000 |
| Preferred Stock Dividends | - | - | - | $7,108,000 |
Fetched: 2026-04-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $47,015,000 | $133,162,000 | $138,854,000 | $211,924,000 |
| Total Assets | $67,699,000 | $150,718,000 | $151,805,000 | $222,288,000 |
| Total Non Current Assets | $2,748,000 | $3,463,000 | $3,586,000 | $550,000 |
| Other Non Current Assets | $385,000 | $357,000 | $352,000 | $395,000 |
| Current Assets | $64,951,000 | $147,255,000 | $148,219,000 | $221,738,000 |
| Other Current Assets | $1,922,000 | $2,106,000 | $2,277,000 | $3,346,000 |
| Prepaid Assets | $1,865,000 | $829,000 | $1,819,000 | $4,770,000 |
| Receivables | $1,133,000 | $1,127,000 | $1,533,000 | $2,091,000 |
| Taxes Receivable | $1,133,000 | $1,127,000 | $1,533,000 | $2,091,000 |
| Cash Cash Equivalents And Short Term Investments | $60,031,000 | $143,193,000 | $142,590,000 | $211,531,000 |
| Cash And Cash Equivalents | $60,031,000 | $143,193,000 | $142,590,000 | $211,531,000 |
| Cash Equivalents | $46,134,000 | $131,613,000 | $87,971,000 | - |
| Cash Financial | $13,897,000 | $11,580,000 | $54,619,000 | - |
| Debt | ||||
| Total Debt | $1,915,000 | $2,494,000 | $2,790,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $1,198,000 | $1,839,000 | $2,275,000 | $0 |
| Current Debt And Capital Lease Obligation | $717,000 | $655,000 | $515,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $20,684,000 | $17,556,000 | $12,951,000 | $10,364,000 |
| Total Non Current Liabilities Net Minority Interest | $1,198,000 | $1,839,000 | $2,275,000 | $59,000 |
| Current Liabilities | $19,486,000 | $15,717,000 | $10,676,000 | $10,305,000 |
| Other Current Liabilities | $500,000 | $563,000 | $1,951,000 | $461,000 |
| Payables And Accrued Expenses | $13,958,000 | $10,274,000 | $6,347,000 | $8,817,000 |
| Payables | $4,661,000 | $3,878,000 | $4,004,000 | $3,928,000 |
| Accounts Payable | $4,661,000 | $3,878,000 | $4,004,000 | $3,928,000 |
| Other Non Current Liabilities | - | - | - | $59,000 |
| Equity | ||||
| Common Stock Equity | $47,015,000 | $133,162,000 | $138,854,000 | $211,924,000 |
| Total Equity Gross Minority Interest | $47,015,000 | $133,162,000 | $138,854,000 | $211,924,000 |
| Stockholders Equity | $47,015,000 | $133,162,000 | $138,854,000 | $211,924,000 |
| Gains Losses Not Affecting Retained Earnings | $-6,851,000 | $-9,669,000 | $-10,141,000 | $-1,489,000 |
| Other Equity Adjustments | $-6,851,000 | $-9,669,000 | $-10,141,000 | $-1,489,000 |
| Retained Earnings | $-359,313,000 | $-263,822,000 | $-177,739,000 | $-106,281,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $65,880,914 | $65,880,914 | $28,815,267 | $28,815,267 |
| Share Issued | $65,880,914 | $65,880,914 | $28,815,267 | $28,815,267 |
| Tangible Book Value | $47,015,000 | $133,162,000 | $138,854,000 | $211,924,000 |
| Invested Capital | $47,015,000 | $133,162,000 | $138,854,000 | $211,924,000 |
| Working Capital | $45,465,000 | $131,538,000 | $137,543,000 | $211,433,000 |
| Capital Lease Obligations | $1,915,000 | $2,494,000 | $2,790,000 | $0 |
| Total Capitalization | $47,015,000 | $133,162,000 | $138,854,000 | $211,924,000 |
| Additional Paid In Capital | $413,113,000 | $406,587,000 | $326,705,000 | $319,665,000 |
| Capital Stock | $66,000 | $66,000 | $29,000 | $29,000 |
| Common Stock | $66,000 | $66,000 | $29,000 | $29,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,198,000 | $1,839,000 | $2,275,000 | $0 |
| Current Capital Lease Obligation | $717,000 | $655,000 | $515,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,311,000 | $4,225,000 | $1,863,000 | $1,027,000 |
| Current Accrued Expenses | $9,297,000 | $6,396,000 | $2,343,000 | $4,889,000 |
| Net PPE | $2,363,000 | $3,106,000 | $3,234,000 | $155,000 |
| Accumulated Depreciation | $-577,000 | $-330,000 | $-115,000 | $-12,000 |
| Gross PPE | $2,940,000 | $3,436,000 | $3,349,000 | $167,000 |
| Other Properties | $2,564,000 | $3,095,000 | $3,037,000 | $68,000 |
| Machinery Furniture Equipment | $376,000 | $341,000 | $312,000 | $99,000 |
| Treasury Shares Number | - | $0 | - | - |
Fetched: 2026-04-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-82,391,000 | $-72,060,000 | $-60,419,000 | $-40,799,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-82,347,000 | $-71,737,000 | $-59,729,000 | $-40,646,000 |
| Cash Flow From Continuing Operating Activities | $-82,347,000 | $-71,737,000 | $-59,729,000 | $-40,646,000 |
| Operating Gains Losses | $3,589,000 | $-331,000 | $-130,000 | $-319,000 |
| Investing Activities | ||||
| Capital Expenditure | $-44,000 | $-323,000 | $-690,000 | $-153,000 |
| Investing Cash Flow | $-44,000 | $-323,000 | $-690,000 | $-153,000 |
| Cash Flow From Continuing Investing Activities | $-44,000 | $-323,000 | $-690,000 | $-153,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $75,058,000 | $0 | $265,056,000 |
| Financing Cash Flow | $0 | $71,860,000 | $0 | $252,951,000 |
| Cash Flow From Continuing Financing Activities | $0 | $71,860,000 | $0 | $252,951,000 |
| Net Common Stock Issuance | $0 | $75,058,000 | $0 | $115,115,000 |
| Common Stock Issuance | $0 | $75,058,000 | $0 | $115,115,000 |
| Net Other Financing Charges | - | $-3,198,000 | - | $-12,105,000 |
| Net Preferred Stock Issuance | - | - | $0 | $149,941,000 |
| Preferred Stock Issuance | - | - | $0 | $149,941,000 |
| Other | ||||
| End Cash Position | $60,299,000 | $143,461,000 | $142,858,000 | $211,799,000 |
| Beginning Cash Position | $143,461,000 | $142,858,000 | $211,799,000 | $3,405,000 |
| Effect Of Exchange Rate Changes | $-771,000 | $803,000 | $-8,522,000 | $-3,758,000 |
| Changes In Cash | $-82,391,000 | $-200,000 | $-60,419,000 | $212,152,000 |
| Net PPE Purchase And Sale | $-44,000 | $-323,000 | $-690,000 | $-153,000 |
| Purchase Of PPE | $-44,000 | $-323,000 | $-690,000 | $-153,000 |
| Change In Working Capital | $2,180,000 | $5,862,000 | $4,192,000 | $-776,000 |
| Change In Other Current Liabilities | $-639,000 | $-604,000 | $-139,000 | $0 |
| Change In Other Current Assets | $-29,000 | $-4,000 | $-44,000 | $-25,000 |
| Change In Payables And Accrued Expense | $3,706,000 | $4,902,000 | $-203,000 | $7,339,000 |
| Change In Accrued Expense | $2,924,000 | $5,028,000 | $-280,000 | $3,933,000 |
| Change In Payable | $782,000 | $-126,000 | $77,000 | $3,406,000 |
| Change In Account Payable | $782,000 | $-126,000 | $77,000 | $3,406,000 |
| Change In Prepaid Assets | $-858,000 | $1,568,000 | $4,578,000 | $-8,090,000 |
| Stock Based Compensation | $6,526,000 | $8,059,000 | $7,040,000 | $1,791,000 |
| Depreciation Amortization Depletion | $849,000 | $756,000 | $540,000 | $2,000 |
| Depreciation And Amortization | $849,000 | $756,000 | $540,000 | $2,000 |
| Depreciation | $849,000 | $756,000 | $540,000 | $2,000 |
| Net Foreign Currency Exchange Gain Loss | $3,589,000 | $-331,000 | $-130,000 | $-319,000 |
| Net Income From Continuing Operations | $-95,491,000 | $-86,083,000 | $-71,458,000 | $-67,879,000 |
| Deferred Tax | - | $0 | $87,000 | $0 |
| Deferred Income Tax | - | $0 | $87,000 | $0 |
| Other Non Cash Items | - | - | - | $26,535,000 |
Fetched: 2026-04-02